Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

• Published in: The American journal of case reports Vol. 18; pp. 890 - 893
• Main Authors: Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 15-08-2017
• Subjects: Adult; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; Crizotinib; Humans; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Neoadjuvant Therapy; Off-Label Use; Pneumonectomy; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - therapeutic use; Pyridines - therapeutic use
• ISSN: 1941-5923; 1941-5923
• DOI: 10.12659/AJCR.903528

BACKGROUND The treatment of locally advanced non-small cell lung cancer involves a combination of chemotherapy, surgery, and radiotherapy. Each case is discussed and the best strategy is chosen individually, following international guidelines. CASE REPORT A 37-year-old man was diagnosed with locally advanced broncho-pulmonary adenocarcinoma (stage IIIA). The disease was stable after 2 cycles of cisplatin plus Navelbine used as neoadjuvant therapy. FISH analysis revealed an ALK rearrangement. The patient then received unlicensed crizotinib as second-line neoadjuvant treatment, which led to an almost complete radiological and metabolic response. A left upper lobectomy was performed, followed by post-operative chemotherapy and radiotherapy. At 18 months post-surgery, the patient is still disease-free according to the last CT scan. CONCLUSIONS Targeted therapy was an alternative solution when chemotherapy was not helping. Randomized studies are needed to define its precise role in the neoadjuvant scheme.